Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Signal12, Inc. (Signal12), a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act through unique neural pathways, today ...

Steroid therapy is the first-line treatment for graft-versus-host disease (GVHD). If GVHD does not respond to initial therapies, doctors may consider chemotherapy, monoclonal antibodies ...

DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

For over a thousand people who undergo a stem cell or bone marrow transplant, survival comes at a cost: graft-versus-host disease (GvHD). 1 GvHD is a life-altering condition which affects 30 to 40 ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Further study is needed in larger populations to verify these outcomes. Despite recent advances, up to 40% of patients develop acute graft-versus-host disease (GVHD) after allogeneic transplant.

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

New treatments for graft-vs.-host disease, updated dosage for HPV vaccines — and Fred Hutch announces awards for graduate students.

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.